

Table 14.2.1.6 Schirmer's test type II (Full analysis set)

Investigational Medicinal Product: rhNGF 20 µg/mL - Dry Eye Severity Level > 2

| Parameter | Visit | Statistics | Full Analysis Set N=9 | | | |
|-----------|-------|------------|--------------------------|----------------------|---------------|----------------------|
| | | | Study Eye | | Non Study Eye | |
| | | | Value | Change from Baseline | Value | Change from Baseline |
| | | Median | 12.0 | 5.0 | 12.0 | -5.0 |
| | | Max | 29 | 24 | 25 | 14 |

Note: Patients are summarised according to the Investigational Medicinal Product they actually received

Baseline: Screening visit assessment

Source: [Listing 16.2.6.6](#) - Schirmer's test type II

Program: Tables\c1116-qs-01-tbl.sas

Table 14.2.1.6 Schirmer's test type II (Full analysis set)

Investigational Medicinal Product: rhNGF 20 µg/mL - Overall Dry Eye Severity Level

| Parameter | Visit | Statistics | Full Analysis Set N=20 | | | |
|--------------------------------------|------------------------|------------|---------------------------|----------------------|---------------|----------------------|
| | | | Study Eye | | Non Study Eye | |
| | | | Value | Change from Baseline | Value | Change from Baseline |
| Schirmer's Test II Result (mm/5 min) | Screening - Day -15/-1 | N | 20 | | 20 | |
| | | Mean | 13.3 | | 15.7 | |

Table 14.2.1.6 Schirmer's test type II (Full analysis set)

Investigational Medicinal Product: rhNGF 20 µg/mL - Overall Dry Eye Severity Level

| Parameter | Visit | Statistics | Full Analysis Set N=20 | | | |
|--------------------------------------|-------------------|------------|---------------------------|----------------------|---------------|----------------------|
| | | | Study Eye | | Non Study Eye | |
| | | | Value | Change from Baseline | Value | Change from Baseline |
| Schirmer's Test II Result (mm/5 min) | Visit 2 - Day 1 | SD | 10.0 | | 10.4 | |
| | | CV% | 75.8 | | 66.0 | |
| | | Min | 2 | | 3 | |
| | | Median | 10.5 | | 15.0 | |
| | | Max | 35 | | 35 | |
| | | N | 20 | 20 | 20 | 20 |
| | | Mean | 11.3 | -2.0 | 13.5 | -2.2 |
| | | SD | 8.7 | 9.5 | 8.7 | 8.4 |
| | | CV% | 77.0 | -488.3 | 64.6 | -383.0 |
| | | Min | 1 | -28 | 3 | -17 |
| Schirmer's Test II Result (mm/5 min) | Visit 3 - Day 8±1 | Median | 8.0 | -1.0 | 12.0 | 0.5 |
| | | Max | 35 | 18 | 35 | 15 |
| | | N | 20 | 20 | 20 | 20 |
| | | Mean | 14.9 | 1.6 | 14.0 | -1.8 |
| | | SD | 10.6 | 13.3 | 10.4 | 10.2 |
| | | CV% | 71.3 | 832.2 | 74.5 | -585.4 |
| Schirmer's Test II Result (mm/5 min) | Visit 3 - Day 8±1 | Min | 3 | -25 | 2 | -16 |

Table 14.2.1.6 Schirmer's test type II (Full analysis set)

Investigational Medicinal Product: rhNGF 20 µg/mL - Overall Dry Eye Severity Level

| Parameter | Visit | Statistics | Full Analysis Set N=20 | | | |
|--------------------------------------|----------------------------|------------|---------------------------|----------------------|---------------|----------------------|
| | | | Study Eye | | Non Study Eye | |
| | | | Value | Change from Baseline | Value | Change from Baseline |
| Schirmer's Test II Result (mm/5 min) | Visit 6 - Day 29±1 | Median | 12.0 | 0.5 | 10.0 | -4.0 |
| | | Max | 35 | 26 | 35 | 23 |
| | | N | 20 | 20 | 20 | 20 |
| | | Mean | 17.0 | 3.8 | 18.1 | 2.4 |
| | | SD | 9.2 | 8.7 | 9.4 | 7.2 |
| | | CV% | 54.0 | 231.5 | 51.9 | 308.2 |
| | | Min | 3 | -16 | 4 | -12 |
| | | Median | 16.5 | 4.0 | 17.0 | 3.0 |
| | | Max | 35 | 22 | 35 | 15 |
| | | | | | | |
| Schirmer's Test II Result (mm/5 min) | Final Visit - Day 56±4/ETV | N | 20 | 20 | 20 | 20 |
| | | Mean | 15.4 | 2.2 | 15.0 | -0.8 |
| | | SD | 9.6 | 11.4 | 8.2 | 8.6 |
| | | CV% | 62.2 | 532.1 | 54.9 | -1146.9 |
| | | Min | 2 | -31 | 2 | -15 |
| | | Median | 12.5 | 4.5 | 14.0 | 0.0 |
| | | Max | 30 | 24 | 27 | 14 |

Table 14.2.1.6 Schirmer's test type II (Full analysis set)

Investigational Medicinal Product: rhNGF 20 µg/mL - Overall Dry Eye Severity Level

| Parameter | Visit | Statistics | Full Analysis Set N=20 | | | |
|-----------|-------|------------|---------------------------|----------------------|---------------|----------------------|
| | | | Study Eye | | Non Study Eye | |
| | | | Value | Change from Baseline | Value | Change from Baseline |

Note: Patients are summarised according to the Investigational Medicinal Product they actually received

Baseline: Screening visit assessment

Source: [Listing 16.2.6.6](#) - Schirmer's test type II

Program: Tables\c116-qs-01-tbl.sas

Table 14.2.1.6 Schirmer's test type II (Full analysis set)

Investigational Medicinal Product: rhNGF 4 µg/mL - Dry Eye Severity Level <= 2

| Parameter | Visit | Statistics | Full Analysis Set N=13 | | | |
|-----------|-------|------------|---------------------------|----------------------|---------------|----------------------|
| | | | Study Eye | | Non Study Eye | |
| | | | Value | Change from Baseline | Value | Change from Baseline |

| | | | | | | |
|--------------------------------------|------------------------|------|------|--|------|--|
| Schirmer's Test II Result (mm/5 min) | Screening - Day -15/-1 | N | 13 | | 13 | |
| | | Mean | 8.0 | | 7.4 | |
| | | SD | 3.7 | | 3.2 | |
| | | CV% | 46.5 | | 43.4 | |

Table 14.2.1.6 Schirmer's test type II (Full analysis set)

Investigational Medicinal Product: rhNGF 4 µg/mL - Dry Eye Severity Level > 2

| Parameter | Visit | Statistics | Full Analysis Set N=7 | | | |
|-----------|-------|------------|--------------------------|----------------------|---------------|----------------------|
| | | | Study Eye | | Non Study Eye | |
| | | | Value | Change from Baseline | Value | Change from Baseline |

Note: Patients are summarised according to the Investigational Medicinal Product they actually received

Baseline: Screening visit assessment

Source: [Listing 16.2.6.6](#) - Schirmer's test type II

Program: Tables\c116-qs-01-tbl.sas

Table 14.2.1.6 Schirmer's test type II (Full analysis set)

Investigational Medicinal Product: rhNGF 4 µg/mL - Overall Dry Eye Severity Level

| Parameter | Visit | Statistics | Full Analysis Set N=20 | | | |
|-----------|-------|------------|---------------------------|----------------------|---------------|----------------------|
| | | | Study Eye | | Non Study Eye | |
| | | | Value | Change from Baseline | Value | Change from Baseline |

| | | | | | | |
|--------------------------------------|------------------------|------|------|--|------|--|
| Schirmer's Test II Result (mm/5 min) | Screening - Day -15/-1 | N | 20 | | 20 | |
| | | Mean | 6.8 | | 7.1 | |
| | | SD | 4.4 | | 3.7 | |
| | | CV% | 64.8 | | 53.0 | |

Table 14.2.1.6 Schirmer's test type II (Full analysis set)

Investigational Medicinal Product: rhNGF 4 µg/mL - Overall Dry Eye Severity Level

| Parameter | Visit | Statistics | Full Analysis Set N=20 | | | |
|--------------------------------------|-----------------|------------|---------------------------|----------------------|---------------|----------------------|
| | | | Study Eye | | Non Study Eye | |
| | | | Value | Change from Baseline | Value | Change from Baseline |
| Schirmer's Test II Result (mm/5 min) | Visit 2 - Day 1 | Min | 0 | | 0 | |
| | | Median | 7.0 | | 7.0 | |
| | | Max | 15 | | 15 | |
| | | N | 20 | 20 | 20 | 20 |
| | | Mean | 9.3 | 2.5 | 9.4 | 2.4 |
| | | SD | 7.6 | 5.7 | 7.1 | 5.2 |
| | | CV% | 81.7 | 228.7 | 76.0 | 223.2 |
| | | Min | 3 | -4 | 2 | -5 |
| | | Median | 7.0 | 0.0 | 9.0 | 1.0 |
| | | Max | 32 | 19 | 35 | 20 |
| | | N | 20 | 20 | 20 | 20 |
| | | Mean | 8.9 | 2.1 | 10.3 | 3.3 |
| | | SD | 6.9 | 5.9 | 6.1 | 4.9 |
| | | CV% | 78.2 | 278.9 | 59.5 | 151.4 |
| | | Min | 1 | -10 | 1 | -10 |
| | | Median | 7.5 | 1.0 | 9.5 | 3.5 |
| | | Max | 29 | 16 | 26 | 11 |

Table 14.2.1.6 Schirmer's test type II (Full analysis set)

Investigational Medicinal Product: rhNGF 4 µg/mL - Overall Dry Eye Severity Level

| Parameter | Visit | Statistics | Full Analysis Set N=20 | | | |
|--------------------------------------|----------------------------|------------|---------------------------|----------------------|---------------|----------------------|
| | | | Study Eye | | Non Study Eye | |
| | | | Value | Change from Baseline | Value | Change from Baseline |
| Schirmer's Test II Result (mm/5 min) | Visit 6 - Day 29±1 | N | 19 | 19 | 19 | 19 |
| | | Mean | 13.2 | 6.5 | 13.5 | 6.4 |
| | | SD | 11.0 | 8.9 | 10.4 | 8.4 |
| | | CV% | 83.4 | 137.3 | 77.3 | 130.4 |
| | | Min | 0 | -9 | 1 | -7 |
| | | Median | 9.0 | 7.0 | 12.0 | 5.0 |
| | | Max | 35 | 25 | 35 | 24 |
| Schirmer's Test II Result (mm/5 min) | Final Visit - Day 56±4/ETV | N | 20 | 20 | 20 | 20 |
| | | Mean | 13.7 | 6.9 | 12.5 | 5.5 |
| | | SD | 8.5 | 5.7 | 9.3 | 7.7 |
| | | CV% | 62.4 | 82.6 | 74.3 | 140.8 |
| | | Min | 0 | -3 | 0 | -8 |
| | | Median | 14.0 | 5.5 | 11.0 | 5.5 |
| | | Max | 30 | 18 | 30 | 21 |

Table 14.2.1.6 Schirmer's test type II (Full analysis set)

Investigational Medicinal Product: rhNGF 4 µg/mL - Overall Dry Eye Severity Level

| Parameter | Visit | Statistics | Full Analysis Set N=20 | | | |
|-----------|-------|------------|---------------------------|----------------------|---------------|----------------------|
| | | | Study Eye | | Non Study Eye | |
| | | | Value | Change from Baseline | Value | Change from Baseline |

Note: Patients are summarised according to the Investigational Medicinal Product they actually received

Baseline: Screening visit assessment

Source: [Listing 16.2.6.6](#) - Schirmer's test type II

Program: Tables\c116-qs-01-tbl.sas

14.2.1.7 TFBUT (FAS)

Table 14.2.1.7 Tear film break-up time (Full analysis set)

Investigational Medicinal Product: rhNGF 20 µg/mL - Dry Eye Severity Level <= 2

| Parameter | Visit | Statistics | Full Analysis Set N=11 | | | |
|---------------------------------------|------------------------|------------|---------------------------|----------------------|---------------|----------------------|
| | | | Study Eye | | Non Study Eye | |
| | | | Value | Change from Baseline | Value | Change from Baseline |
| Average Tear Film Break-Up Time (sec) | Screening - Day -15/-1 | N | 11 | | 11 | |
| | | Mean | 3.9 | | 4.7 | |

Table 14.2.1.21 Schirmer's test type II (Per protocol set)

Investigational Medicinal Product: rhNGF 20 µg/mL - Dry Eye Severity Level > 2

| Parameter | Visit | Statistics | Per Protocol Set N=6 | | | |
|-----------|-------|------------|-------------------------|----------------------|---------------|----------------------|
| | | | Study Eye | | Non Study Eye | |
| | | | Value | Change from Baseline | Value | Change from Baseline |
| | | Median | 15.5 | 6.0 | 18.0 | -6.5 |
| | | Max | 29 | 24 | 25 | 14 |

Note: Patients are summarised according to the Investigational Medicinal Product they actually received

Baseline: Screening visit assessment

Source: [Listing 16.2.6.6](#) - Schirmer's test type II

Program: Tables\c1116-qs-01-tbl.sas

Table 14.2.1.21 Schirmer's test type II (Per protocol set)

Investigational Medicinal Product: rhNGF 20 µg/mL - Overall Dry Eye Severity Level

| Parameter | Visit | Statistics | Per Protocol Set N=14 | | | |
|--------------------------------------|------------------------|------------|--------------------------|----------------------|---------------|----------------------|
| | | | Study Eye | | Non Study Eye | |
| | | | Value | Change from Baseline | Value | Change from Baseline |
| Schirmer's Test II Result (mm/5 min) | Screening - Day -15/-1 | N | 14 | | 14 | |
| | | Mean | 9.9 | | 14.1 | |

Table 14.2.1.21 Schirmer's test type II (Per protocol set)

Investigational Medicinal Product: rhNGF 20 µg/mL - Overall Dry Eye Severity Level

| Parameter | Visit | Statistics | Per Protocol Set N=14 | | | |
|--------------------------------------|-------------------|------------|--------------------------|----------------------|---------------|----------------------|
| | | | Study Eye | | Non Study Eye | |
| | | | Value | Change from Baseline | Value | Change from Baseline |
| Schirmer's Test II Result (mm/5 min) | Visit 2 - Day 1 | SD | 6.2 | | 10.0 | |
| | | CV% | 62.5 | | 70.5 | |
| | | Min | 2 | | 3 | |
| | | Median | 8.5 | | 11.5 | |
| | | Max | 22 | | 31 | |
| | | N | 14 | 14 | 14 | 14 |
| | | Mean | 10.6 | 0.8 | 13.8 | -0.4 |
| | | SD | 7.5 | 7.9 | 7.6 | 8.2 |
| | | CV% | 70.1 | 1011.0 | 55.2 | -2289.5 |
| | | Min | 1 | -15 | 3 | -16 |
| Schirmer's Test II Result (mm/5 min) | Visit 3 - Day 8±1 | Median | 8.0 | -1.0 | 12.5 | 2.0 |
| | | Max | 25 | 18 | 35 | 15 |
| | | N | 14 | 14 | 14 | 14 |
| | | Mean | 15.0 | 5.1 | 14.7 | 0.6 |
| | | SD | 10.5 | 9.8 | 11.0 | 9.7 |
| | | CV% | 70.3 | 191.0 | 74.9 | 1697.7 |
| Schirmer's Test II Result (mm/5 min) | Visit 3 - Day 8±1 | Min | 3 | -6 | 2 | -10 |

Table 14.2.1.21 Schirmer's test type II (Per protocol set)

Investigational Medicinal Product: rhNGF 20 µg/mL - Overall Dry Eye Severity Level

| Parameter | Visit | Statistics | Per Protocol Set N=14 | | | |
|--------------------------------------|----------------------------|------------|--------------------------|----------------------|---------------|----------------------|
| | | | Study Eye | | Non Study Eye | |
| | | | Value | Change from Baseline | Value | Change from Baseline |
| Schirmer's Test II Result (mm/5 min) | Visit 6 - Day 29±1 | Median | 12.0 | 2.0 | 10.5 | -1.0 |
| | | Max | 35 | 26 | 35 | 23 |
| | | N | 14 | 14 | 14 | 14 |
| | | Mean | 15.8 | 5.9 | 16.6 | 2.4 |
| | | SD | 8.9 | 7.6 | 9.7 | 8.2 |
| | | CV% | 56.4 | 128.5 | 58.4 | 336.0 |
| | | Min | 3 | -5 | 4 | -12 |
| | | Median | 14.5 | 4.5 | 17.0 | 3.0 |
| | | Max | 35 | 22 | 35 | 15 |
| | | | | | | |
| Schirmer's Test II Result (mm/5 min) | Final Visit - Day 56±4/ETV | N | 14 | 14 | 14 | 14 |
| | | Mean | 14.5 | 4.6 | 14.2 | 0.1 |
| | | SD | 8.7 | 9.7 | 7.0 | 9.5 |
| | | CV% | 60.0 | 209.1 | 49.0 | 13275.5 |
| | | Min | 2 | -11 | 2 | -15 |
| | | Median | 12.5 | 5.0 | 14.0 | 0.5 |
| | | Max | 29 | 24 | 25 | 14 |

Table 14.2.1.21 Schirmer's test type II (Per protocol set)

Investigational Medicinal Product: rhNGF 4 µg/mL - Dry Eye Severity Level > 2

| Parameter | Visit | Statistics | Per Protocol Set N=5 | | | |
|-----------|-------|------------|-------------------------|----------------------|---------------|----------------------|
| | | | Study Eye | | Non Study Eye | |
| | | | Value | Change from Baseline | Value | Change from Baseline |

Note: Patients are summarised according to the Investigational Medicinal Product they actually received

Baseline: Screening visit assessment

Source: [Listing 16.2.6.6](#) - Schirmer's test type II

Program: Tables\c116-qs-01-tbl.sas

Table 14.2.1.21 Schirmer's test type II (Per protocol set)

Investigational Medicinal Product: rhNGF 4 µg/mL - Overall Dry Eye Severity Level

| Parameter | Visit | Statistics | Per Protocol Set N=16 | | | |
|-----------|-------|------------|--------------------------|----------------------|---------------|----------------------|
| | | | Study Eye | | Non Study Eye | |
| | | | Value | Change from Baseline | Value | Change from Baseline |

| | | | | | | |
|--------------------------------------|------------------------|------|------|--|------|--|
| Schirmer's Test II Result (mm/5 min) | Screening - Day -15/-1 | N | 16 | | 16 | |
| | | Mean | 7.8 | | 7.9 | |
| | | SD | 4.1 | | 3.4 | |
| | | CV% | 52.6 | | 43.7 | |

Table 14.2.1.21 Schirmer's test type II (Per protocol set)

Investigational Medicinal Product: rhNGF 4 µg/mL - Overall Dry Eye Severity Level

| Parameter | Visit | Statistics | Per Protocol Set N=16 | | | |
|--------------------------------------|-----------------|------------|--------------------------|----------------------|---------------|----------------------|
| | | | Study Eye | | Non Study Eye | |
| | | | Value | Change from Baseline | Value | Change from Baseline |
| Schirmer's Test II Result (mm/5 min) | Visit 2 - Day 1 | Min | 0 | | 1 | |
| | | Median | 8.5 | | 8.0 | |
| | | Max | 15 | | 15 | |
| | | N | 16 | 16 | 16 | 16 |
| | | Mean | 10.1 | 2.4 | 10.6 | 2.7 |
| | | SD | 8.1 | 6.3 | 7.5 | 5.3 |
| | | CV% | 80.2 | 263.6 | 70.7 | 197.7 |
| | | Min | 3 | -4 | 4 | -2 |
| | | Median | 8.0 | 0.0 | 9.0 | 1.0 |
| | | Max | 32 | 19 | 35 | 20 |
| | | N | 16 | 16 | 16 | 16 |
| | | Mean | 10.1 | 2.4 | 11.6 | 3.8 |
| | | SD | 7.2 | 6.4 | 6.2 | 5.2 |
| | | CV% | 71.0 | 268.9 | 52.9 | 138.9 |
| | | Min | 1 | -10 | 1 | -10 |
| | | Median | 9.0 | 1.0 | 12.0 | 4.0 |
| | | Max | 29 | 16 | 26 | 11 |

Table 14.2.1.21 Schirmer's test type II (Per protocol set)

Investigational Medicinal Product: rhNGF 4 µg/mL - Overall Dry Eye Severity Level

| Parameter | Visit | Statistics | Per Protocol Set N=16 | | | |
|--------------------------------------|----------------------------|------------|--------------------------|----------------------|---------------|----------------------|
| | | | Study Eye | | Non Study Eye | |
| | | | Value | Change from Baseline | Value | Change from Baseline |
| Schirmer's Test II Result (mm/5 min) | Visit 6 - Day 29±1 | N | 16 | 16 | 16 | 16 |
| | | Mean | 15.0 | 7.3 | 15.6 | 7.8 |
| | | SD | 11.0 | 9.4 | 9.9 | 8.4 |
| | | CV% | 73.6 | 129.0 | 63.6 | 108.2 |
| | | Min | 0 | -9 | 4 | -7 |
| | | Median | 13.5 | 7.0 | 13.0 | 8.5 |
| | | Max | 35 | 25 | 35 | 24 |
| Schirmer's Test II Result (mm/5 min) | Final Visit - Day 56±4/ETV | N | 16 | 16 | 16 | 16 |
| | | Mean | 15.1 | 7.4 | 14.8 | 6.9 |
| | | SD | 8.7 | 6.2 | 8.9 | 7.7 |
| | | CV% | 57.3 | 83.9 | 60.2 | 110.6 |
| | | Min | 0 | -3 | 3 | -8 |
| | | Median | 17.0 | 7.0 | 16.0 | 7.5 |
| | | Max | 30 | 18 | 30 | 21 |

Table 14.2.1.21 Schirmer's test type II (Per protocol set)

Investigational Medicinal Product: rhNGF 4 µg/mL - Overall Dry Eye Severity Level

| Parameter | Visit | Statistics | Per Protocol Set N=16 | | | |
|-----------|-------|------------|--------------------------|----------------------|---------------|----------------------|
| | | | Study Eye | | Non Study Eye | |
| | | | Value | Change from Baseline | Value | Change from Baseline |

Note: Patients are summarised according to the Investigational Medicinal Product they actually received

Baseline: Screening visit assessment

Source: [Listing 16.2.6.6](#) - Schirmer's test type II

Program: Tables\c116-qs-01-tbl.sas

14.2.1.22 TFBUT (PP set)

Table 14.2.1.22 Tear film break-up time (Per protocol set)

Investigational Medicinal Product: rhNGF 20 µg/mL - Dry Eye Severity Level <= 2

| Parameter | Visit | Statistics | Per Protocol Set N=8 | | | |
|---------------------------------------|------------------------|------------|-------------------------|----------------------|---------------|----------------------|
| | | | Study Eye | | Non Study Eye | |
| | | | Value | Change from Baseline | Value | Change from Baseline |
| Average Tear Film Break-Up Time (sec) | Screening - Day -15/-1 | N | 8 | | 8 | |
| | | Mean | 4.4 | | 5.3 | |